E
Exelixis
Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer
At a glance
- Status
- Listed
- Listing
- IPO 2000
Open roles
Exelixis in the San Francisco ecosystem
The Exelixis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
- PAPaineWebber
- SPStelios Papadopoulos
Atlas Venture- OPOxford Bioscience Partners
Series A4 investors entered at this stage
- HMHambrecht & Quist Capital Management
- DADomain Associates
- PFPfizer
- AIAdvent International
Series B and later2 investors entered at this stage
- UCUniversity of California
- BEBerkeley
Source: Dealroom Talent Intelligence.
Alumni founders
Former Exelixis employees who went on to found companies, sorted by Dealroom signal score.
Jonathan LightnerUnited States
VBVentyx BiosciencesEst. 2018
Raju MohanUnited States
XTXaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
GBGrove BiopharmaEst. 2020
Geoffrey M. Duyk, M.D., Ph.D.United StatesPatents
106 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Exelixis was the backer or acquirer, 2000–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across Exelixis's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Exelixis's portfolio, mapped.
See Exelixis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
FDA extends review of Exelixis' zanzalintinib combo for colorectal cancer, decision due March 2027
